This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tozer, G. M. Articles by Chaplin, D. J. Search for Related Content PubMed PubMed Citation Articles by Tozer, G. M. Articles by Chaplin, D. J.

Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent

Early Effects in Tumors and Normal Tissues¹

Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, United Kingdom

The potential for tumor vascular-targeting by using the tubulin destabilizing agent disodium combretastatin A-4 3-0-phosphate (CA-4-P) was assessed in a rat system. This approach aims to shut down the established tumor vasculature, leading to the development of extensive tumor cell necrosis. The early vascular effects of CA-4-P were assessed in the s.c. implanted P22 carcinosarcoma and in a range of normal tissues. Blood flow was measured by the uptake of radiolabeled iodoantipyrine, and quantitative autoradiography was used to measure spatial heterogeneity of blood flow in tumor sections. CA-4-P (100 mg/kg i.p.) caused a significant increase in mean arterial blood pressure at 1 and 6 h after treatment and a very large decrease in tumor blood flow, which—by 6 h—was reduced approximately 100-fold. The spleen was the most affected normal tissue with a 7-fold reduction in blood flow at 6 h. Calculations of vascular resistance revealed some vascular changes in the heart and kidney for which there were no significant changes in blood flow. Quantitative autoradiography showed that CA-4-P increased the spatial heterogeneity in tumor blood flow. The drug affected peripheral tumor regions less than central regions. Administration of CA-4-P (30 mg/kg) in the presence of the nitric oxide synthase inhibitor, N-nitro-L-arginine methyl ester, potentiated the effect of CA-4-P in tumor tissue. The combination increased tumor vascular resistance 300-fold compared with less than 7-fold for any of the normal tissues. This shows that tissue production of nitric oxide protects against the damaging vascular effects of CA-4-P. Significant changes in tumor vascular resistance could also be obtained in isolated tumor perfusions using a cell-free perfusate, although the changes were much less than those observed in vivo. This shows that the action of CA-4-P includes mechanisms other than those involving red cell viscosity, intravascular coagulation, and neutrophil adhesion. The uptake of CA-4-P and combretastatin A-4 (CA-4) was more efficient in tumor than in skeletal muscle tissue and dephosphorylation of CA-4-P to CA-4 was faster in the former. These results are promising for the use of CA-4-P as a tumor vascular-targeting agent.

This article has been cited by other articles:

				S. Aprile, E. Del Grosso, G. C. Tron, and G. Grosa In Vitro Metabolism Study of Combretastatin A-4 in Rat and Human Liver Microsomes Drug Metab. Dispos., December 1, 2007; 35(12): 2252 - 2261. [Abstract] [Full Text] [PDF]

				T. J. Kim, M. Ravoori, C. N. Landen, A. A. Kamat, L. Y. Han, C. Lu, Y. G. Lin, W. M. Merritt, N. Jennings, W. A. Spannuth, et al. Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma Cancer Res., October 1, 2007; 67(19): 9337 - 9345. [Abstract] [Full Text] [PDF]

				H.-L. Lin, S.-H. Chiou, C.-W. Wu, W.-B. Lin, L.-H. Chen, Y.-P. Yang, M.-L. Tsai, Y.-H. Uen, J.-P. Liou, and C.-W. Chi Combretastatin A4-Induced Differential Cytotoxicity and Reduced Metastatic Ability by Inhibition of AKT Function in Human Gastric Cancer Cells J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 365 - 373. [Abstract] [Full Text] [PDF]

				M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF]

				C. Kanthou, S. Kranjc, G. Sersa, G. Tozer, A. Zupanic, and M. Cemazar The endothelial cytoskeleton as a target of electroporation-based therapies Mol. Cancer Ther., December 1, 2006; 5(12): 3145 - 3152. [Abstract] [Full Text] [PDF]

				W. Badn, S. Kalliomaki, B. Widegren, and H. O. Sjogren Low-Dose Combretastatin A4 Phosphate Enhances the Immune Response of Tumor Hosts to Experimental Colon Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4714 - 4719. [Abstract] [Full Text] [PDF]

				H. C. Thoeny, F. De Keyzer, V. Vandecaveye, F. Chen, X. Sun, H. Bosmans, R. Hermans, E. K. Verbeken, C. Boesch, G. Marchal, et al. Effect of Vascular Targeting Agent in Rat Tumor Model: Dynamic Contrast-enhanced versus Diffusion-weighted MR Imaging Radiology, November 1, 2005; 237(2): 492 - 499. [Abstract] [Full Text] [PDF]

				D. Dong, B. Ko, P. Baumeister, S. Swenson, F. Costa, F. Markland, C. Stiles, J. B. Patterson, S. E. Bates, and A. S. Lee Vascular Targeting and Antiangiogenesis Agents Induce Drug Resistance Effector GRP78 within the Tumor Microenvironment Cancer Res., July 1, 2005; 65(13): 5785 - 5791. [Abstract] [Full Text] [PDF]

				M. Belleri, D. Ribatti, S. Nicoli, F. Cotelli, L. Forti, V. Vannini, L. A. Stivala, and M. Presta Antiangiogenic and Vascular-Targeting Activity of the Microtubule-Destabilizing trans-Resveratrol Derivative 3,5,4'-Trimethoxystilbene Mol. Pharmacol., May 1, 2005; 67(5): 1451 - 1459. [Abstract] [Full Text] [PDF]

				H. C. Thoeny, F. De Keyzer, F. Chen, Y. Ni, W. Landuyt, E. K. Verbeken, H. Bosmans, G. Marchal, and R. Hermans Diffusion-weighted MR Imaging in Monitoring the Effect of a Vascular Targeting Agent on Rhabdomyosarcoma in Rats Radiology, March 1, 2005; 234(3): 756 - 764. [Abstract] [Full Text] [PDF]

				P. R. Wachsberger, R. Burd, N. Marero, C. Daskalakis, A. Ryan, P. McCue, and A. P. Dicker Effect of the Tumor Vascular-Damaging Agent, ZD6126, on the Radioresponse of U87 Glioblastoma Clin. Cancer Res., January 15, 2005; 11(2): 835 - 842. [Abstract] [Full Text] [PDF]

				E. Escalona-Benz, M.-E. Jockovich, T. G. Murray, B. Hayden, E. Hernandez, W. Feuer, and J. J. Windle Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 8 - 11. [Abstract] [Full Text] [PDF]

				C. Kanthou, O. Greco, A. Stratford, I. Cook, R. Knight, O. Benzakour, and G. Tozer The Tubulin-Binding Agent Combretastatin A-4-Phosphate Arrests Endothelial Cells in Mitosis and Induces Mitotic Cell Death Am. J. Pathol., October 1, 2004; 165(4): 1401 - 1411. [Abstract] [Full Text] [PDF]

				P. E. Thorpe Vascular Targeting Agents as Cancer Therapeutics Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427. [Abstract] [Full Text] [PDF]

				M. M. Cooney, T. Radivoyevitch, A. Dowlati, B. Overmoyer, N. Levitan, K. Robertson, S. L. Levine, K. DeCaro, C. Buchter, A. Taylor, et al. Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer Clin. Cancer Res., January 1, 2004; 10(1): 96 - 100. [Abstract] [Full Text] [PDF]

				J. P. Stevenson, M. Rosen, W. Sun, M. Gallagher, D. G. Haller, D. Vaughn, B. Giantonio, R. Zimmer, W. P. Petros, M. Stratford, et al. Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow J. Clin. Oncol., December 1, 2003; 21(23): 4428 - 4438. [Abstract] [Full Text] [PDF]

				G M Tozer Measuring tumour vascular response to antivascular and antiangiogenic drugs Br. J. Radiol., December 1, 2003; 76(suppl_1): S23 - S35. [Abstract] [Full Text] [PDF]

				S M Galbraith Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development Br. J. Radiol., December 1, 2003; 76(suppl_1): S83 - S86. [Full Text] [PDF]

				H. Nambu, R. Nambu, M. Melia, and P. A. Campochiaro Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3650 - 3655. [Abstract] [Full Text] [PDF]

				J. M. Collins Functional Imaging in Phase I Studies: Decorations or Decision Making? J. Clin. Oncol., August 1, 2003; 21(15): 2807 - 2809. [Full Text] [PDF]

				G. J.S. Rustin, S. M. Galbraith, H. Anderson, M. Stratford, L. K. Folkes, L. Sena, L. Gumbrell, and P. M. Price Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results J. Clin. Oncol., August 1, 2003; 21(15): 2815 - 2822. [Abstract] [Full Text] [PDF]

				H. L. Anderson, J. T. Yap, M. P. Miller, A. Robbins, T. Jones, and P. M. Price Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate J. Clin. Oncol., August 1, 2003; 21(15): 2823 - 2830. [Abstract] [Full Text] [PDF]

				S. M. Galbraith, R. J. Maxwell, M. A. Lodge, G. M. Tozer, J. Wilson, N. J. Taylor, J. J. Stirling, L. Sena, A. R. Padhani, and G. J.S. Rustin Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging J. Clin. Oncol., August 1, 2003; 21(15): 2831 - 2842. [Abstract] [Full Text] [PDF]

				P. Wachsberger, R. Burd, and A. P. Dicker Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971. [Abstract] [Full Text] [PDF]

				P. D. Davis, G. J. Dougherty, D. C. Blakey, S. M. Galbraith, G. M. Tozer, A. L. Holder, M. A. Naylor, J. Nolan, M. R. L. Stratford, D. J. Chaplin, et al. ZD6126: A Novel Vascular-targeting Agent That Causes Selective Destruction of Tumor Vasculature Cancer Res., December 15, 2002; 62(24): 7247 - 7253. [Abstract] [Full Text] [PDF]

				B. M. Seddon, R. J. Maxwell, D. J. Honess, R. Grimshaw, F. Raynaud, G. M. Tozer, and P. Workman Validation of the Fluorinated 2-Nitroimidazole SR-4554 as a Noninvasive Hypoxia Marker Detected by Magnetic Resonance Spectroscopy Clin. Cancer Res., July 1, 2002; 8(7): 2323 - 2335. [Abstract] [Full Text] [PDF]

				A. Dowlati, K. Robertson, M. Cooney, W. P. Petros, M. Stratford, J. Jesberger, N. Rafie, B. Overmoyer, V. Makkar, B. Stambler, et al. A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer Cancer Res., June 1, 2002; 62(12): 3408 - 3416. [Abstract] [Full Text] [PDF]

				D. C. Blakey, F. R. Westwood, M. Walker, G. D. Hughes, P. D. Davis, S. E. Ashton, and A. J. Ryan Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models Clin. Cancer Res., June 1, 2002; 8(6): 1974 - 1983. [Abstract] [Full Text] [PDF]

				C. Kanthou and G. M. Tozer The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells Blood, March 15, 2002; 99(6): 2060 - 2069. [Abstract] [Full Text] [PDF]

				J. Griggs, J. N. Skepper, G. A. Smith, K. M. Brindle, J. C. Metcalfe, and R. Hesketh Inhibition of Proliferative Retinopathy by the Anti-Vascular Agent Combretastatin-A4 Am. J. Pathol., March 1, 2002; 160(3): 1097 - 1103. [Abstract] [Full Text] [PDF]

				G. M. Tozer, V. E. Prise, J. Wilson, M. Cemazar, S. Shan, M. W. Dewhirst, P. R. Barber, B. Vojnovic, and D. J. Chaplin Mechanisms Associated with Tumor Vascular Shut-Down Induced by Combretastatin A-4 Phosphate: Intravital Microscopy and Measurement of Vascular Permeability Cancer Res., September 1, 2001; 61(17): 6413 - 6422. [Abstract] [Full Text] [PDF]

				D. A. Beauregard, S. A. Hill, D. J. Chaplin, and K. M. Brindle The Susceptibility of Tumors to the Antivascular Drug Combretastatin A4 Phosphate Correlates with Vascular Permeability Cancer Res., September 1, 2001; 61(18): 6811 - 6815. [Abstract] [Full Text] [PDF]

				R. B. Pedley, S. A. Hill, G. M. Boxer, A. A. Flynn, R. Boden, R. Watson, J. Dearling, D. J. Chaplin, and R. H. J. Begent Eradication of Colorectal Xenografts by Combined Radioimmunotherapy and Combretastatin A-4 3-O-Phosphate Cancer Res., June 1, 2001; 61(12): 4716 - 4722. [Abstract] [Full Text] [PDF]

				A. S. Boehle, B. Sipos, U. Kliche, H. Kalthoff, and P. Dohrmann Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model Ann. Thorac. Surg., May 1, 2001; 71(5): 1657 - 1665. [Abstract] [Full Text] [PDF]

				M. S. Gee, H. M. Saunders, J. C. Lee, J. F. Sanzo, W. T. Jenkins, S. M. Evans, G. Trinchieri, C. M. Sehgal, M. D. Feldman, and W. M. F. Lee Doppler Ultrasound Imaging Detects Changes in Tumor Perfusion during Antivascular Therapy Associated with Vascular Anatomic Alterations Cancer Res., April 1, 2001; 61(7): 2974 - 2982. [Abstract] [Full Text]

				C. Malcontenti-Wilson, V. Muralidharan, S. Skinner, C. Christophi, D. Sherris, and P. E. O’Brien Combretastatin A4 Prodrug Study of Effect on the Growth and the Microvasculature of Colorectal Liver Metastases in a Murine Model Clin. Cancer Res., April 1, 2001; 7(4): 1052 - 1060. [Abstract] [Full Text]

				B. G. Siim, W. T. Laux, M. D. Rutland, B. N. Palmer, and W. R. Wilson Scintigraphic Imaging of the Hypoxia Marker 99mTechnetium-labeled 2,2'-(1,4-Diaminobutane)bis(2-methyl-3-butanone) Dioxime (99mTc-labeled HL-91; Prognox): Noninvasive Detection of Tumor Response to the Antivascular Agent 5,6-Dimethylxanthenone-4-acetic Acid Cancer Res., August 1, 2000; 60(16): 4582 - 4588. [Abstract] [Full Text]

				Y. GUO, A. A.-R. HIGAZI, A. ARAKELIAN, B. S. SACHAIS, D. CINES, R. H. GOLDFARB, T. R. JONES, H. KWAAN, A. P. MAZAR, and S. A. RABBANI A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo FASEB J, July 1, 2000; 14(10): 1400 - 1410. [Abstract] [Full Text]

				Y. S. Lew, S. L. Brown, R. J. Griffin, C. W. Song, and J. H. Kim Arsenic Trioxide Causes Selective Necrosis in Solid Murine Tumors by Vascular Shutdown Cancer Res., December 1, 1999; 59(24): 6033 - 6037. [Abstract] [Full Text] [PDF]